U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Little J, Wilson B, Carter R, et al. Multigene Panels in Prostate Cancer Risk Assessment. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. (Evidence Reports/Technology Assessments, No. 209.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Multigene Panels in Prostate Cancer Risk Assessment

Multigene Panels in Prostate Cancer Risk Assessment.

Show details

References

1.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Canc. 2010;127(12):2893–917. [PubMed: 21351269]
2.
American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010. [June 12, 2012]. www​.cancer.org/acs/groups​/content/@epidemiologysurveilance​/documents​/document/acspc-026238.pdf.
3.
Canadian Cancer Society. Canadian Cancer Statistics 2010. Toronto: Canadian Cancer Society; Apr, 2010.
4.
National Cancer Institute SEER (Surveillance, Epidemiology, and End Results Program of the National Cancer Institute). SEER stat fact sheets: Prostate. May 9, 2011. [June 12, 2012]. 2011 May 9. www​.seer.cancer.gov/statfacts​/html/prost.html.
5.
Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Canc Inst. 2009;101(18):1280–3. [PMC free article: PMC2744729] [PubMed: 19713548]
6.
Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64. [PubMed: 12642065]
7.
Evans S, Metcalfe C, Ibrahim F, et al. Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis. Int J Canc. 2008;123(2):430–5. [PubMed: 18452170]
8.
Delongchamps NB, Singh A, Haas GP. Epidemiology of prostate cancer in Africa: Another step in the understanding of the disease? Curr Probl Canc. 2007;31(3):226–36. [PubMed: 17543950]
9.
Parkin DM, Sitas F, Chirenje M, et al. Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol. 2008;9(7):683–92. [PubMed: 18598933]
10.
Bruner DW, Moore D, Parlanti A, et al. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Canc. 2003;107(5):797–803. [PubMed: 14566830]
11.
Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: A meta-analysis. Canc. 2003;97(8):1894–903. [PubMed: 12673715]
12.
Bratt O. Hereditary prostate cancer: Clinical aspects. J Urol. 2002;168(3):906–13. [PubMed: 12187189]
13.
Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85. [PubMed: 10891514]
14.
Carter BS, Beaty TH, Steinberg GD, et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA. 1992;89(8):3367–71. [PMC free article: PMC48868] [PubMed: 1565627]
15.
Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol. 1993;150(3):797–802. [PubMed: 8345587]
16.
Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008;149(7):461–8. [PMC free article: PMC2584869] [PubMed: 18838726]
17.
Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: A meta-analysis. Diabetologia. 2004;47(6):1071–8. [PubMed: 15164171]
18.
Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Canc Epidemiol Biomarkers Prev. 2006;15(11):2056–62. [PubMed: 17119028]
19.
Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Canc Inst. 1998;90(6):440–6. [PubMed: 9521168]
20.
Alkhenizan A, Hafez K. The role of vitamin E in the prevention of cancer: A meta-analysis of randomized controlled trials. Ann Saudi Med. 2007;27(6):409–14. [PMC free article: PMC6074169] [PubMed: 18059122]
21.
Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: The Physicians' Health Study II randomized controlled trial. JAMA. 2009;301(1):52–62. [PMC free article: PMC2774210] [PubMed: 19066368]
22.
Klein EA, Thompson IM Jr., Tangen CM, et al. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56. [PMC free article: PMC4169010] [PubMed: 21990298]
23.
Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39–51. [PMC free article: PMC3682779] [PubMed: 19066370]
24.
Dagnelie PC, Schuurman AG, Goldbohm RA, et al. Diet, anthropometric measures and prostate cancer risk: A review of prospective cohort and intervention studies. BJU Int. 2004;93(8):1139–50. [PubMed: 15142129]
25.
Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: A meta-analysis of observational studies. Canc Epidemiol Biomarkers Prev. 2004;13(3):340–5. [PubMed: 15006906]
26.
Hwang YW, Kim SY, Jee SH, et al. Soy food consumption and risk of prostate cancer: A meta-analysis of observational studies. Nutr Canc. 2009;61(5):598–606. [PubMed: 19838933]
27.
Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: A revisit of a meta-analysis. Am J Clin Nutr. 2009;89(4):1155–63. [PubMed: 19211820]
28.
Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: A meta-analysis. J Natl Canc Inst. 2005;97(23):1768–77. [PubMed: 16333032]
29.
Qin LQ, Xu JY, Wang PY, et al. Milk consumption is a risk factor for prostate cancer in Western countries: Evidence from cohort studies. Asia Pac J Clin Nutr. 2007;16(3):467–76. [PubMed: 17704029]
30.
Dennis LK. Meta-analysis for combining relative risks of alcohol consumption and prostate cancer. Prostate. 2000;42(1):56–66. [PubMed: 10579799]
31.
Park CH, Myung SK, Kim TY, et al. Coffee consumption and risk of prostate cancer: A meta-analysis of epidemiological studies. BJU Int. 2010;106(6):762–9. [PubMed: 20590551]
32.
Suzuki R, Allen NE, Key TJ, et al. A prospective analysis of the association between dietary fiber intake and prostate cancer risk in EPIC. Int J Canc. 2009;124(1):245–9. [PubMed: 18814263]
33.
Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: A review and meta-analysis. Am J Clin Nutr. 2010;92(5):1223–33. [PubMed: 20844069]
34.
Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: A systematic review and metaanalysis of randomized controlled trials. Int J Canc. 2010;127(1):172–84. [PubMed: 19876916]
35.
Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(2):87–95. [PubMed: 19198622]
36.
MacInnis RJ, English DR. Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Canc Causes Contr. 2006;17(8):989–1003. [PubMed: 16933050]
37.
Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiol. 2002;13(1):72–9. [PubMed: 11805589]
38.
Dennis LK, Coughlin JA, McKinnon BC, et al. Sexually transmitted infections and prostate cancer among men in the U.S. military. Canc Epidemiol Biomarkers Prev. 2009;18(10):2665–71. [PubMed: 19755645]
39.
Rusmevichientong A, Chow SA. Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease. Immunol Res. 2010;48(1-3):27–39. [PubMed: 20717743]
40.
Dennis LK, Dawson DV, Resnick MI. Vasectomy and the risk of prostate cancer: A meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy. Prostate Canc Prostatic Dis. 2002;5(3):193–203. [PubMed: 12496981]
41.
Tang LF, Jiang H, Shang XJ, et al. Vasectomy not associated with prostate cancer: A meta-analysis. Zhonghua Nan Ke Xue. 2009;15(6):545–50. [PubMed: 19593998]
42.
Ballard T, Lagorio S, De AG, et al. Cancer incidence and mortality among flight personnel: A meta-analysis. Aviat Space Environ Med. 2000;71(3):216–24. [PubMed: 10716165]
43.
Buja A, Lange JH, Perissinotto E, et al. Cancer incidence among male military and civil pilots and flight attendants: An analysis on published data. Toxicol Ind Health. 2005;21(10):273–82. [PubMed: 16463960]
44.
Van Maele-Fabry G, Willems JL. Prostate cancer among pesticide applicators: A meta-analysis. Int Arch Occup Environ Health. 2004;77(8):559–70. [PubMed: 15688248]
45.
Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis. Int J Canc. 2010;127(7):1680–91. [PubMed: 20091856]
46.
Browning DR, Martin RM. Statins and risk of cancer: A systematic review and meta-analysis. Int J Canc. 2007;120(4):833–43. [PubMed: 17131313]
47.
Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Canc. 2008;123(4):899–904. [PubMed: 18491405]
48.
Huncharek M, Haddock KS, Reid R, et al. Smoking as a risk factor for prostate cancer: A meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100(4):693–701. [PMC free article: PMC2836346] [PubMed: 19608952]
49.
Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med. 2009;7:36. [PMC free article: PMC2744672] [PubMed: 19638245]
50.
Gilbert R, Metcalfe C, Oliver SE, et al. Life course sun exposure and risk of prostate cancer: Population-based nested case-control study and meta-analysis. Int J Canc. 2009;125(6):1414–23. [PMC free article: PMC2873563] [PubMed: 19444909]
51.
Yin L, Raum E, Haug U, et al. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Canc Epidemiol. 2009;33(6):435–45. [PubMed: 19939760]
52.
Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Canc. 2011;128(6):1414–24. [PubMed: 20473927]
53.
Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Canc. 2006;95(9):1186–94. [PMC free article: PMC2360576] [PubMed: 17077805]
54.
Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Canc. 1977;20(5):680–8. [PubMed: 924691]
55.
Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases. Vivo. 1994;8(3):439–43. [PubMed: 7803731]
56.
Sanchez-Chapado M, Olmedilla G, Cabeza M, et al. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: An autopsy study. Prostate. 2003;54(3):238–47. [PubMed: 12518329]
57.
Soos G, Tsakiris I, Szanto J, et al. The prevalence of prostate carcinoma and its precursor in Hungary: An autopsy study. Eur Urol. 2005;48(5):739–44. [PubMed: 16203079]
58.
Stamatiou K, Alevizos A, Agapitos E, et al. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: An autopsy study. Prostate. 2006;66(12):1319–28. [PubMed: 16688747]
59.
Orde MM, Whitaker NJ, Lawson JS. High prevalence of prostatic neoplasia in Australian men. Pathology. 2009;41(5):433–5. [PubMed: 19900081]
60.
Haas GP, Delongchamps NB, Jones RF, et al. Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007;99(19):1484–9. [PubMed: 17895474]
61.
Oon SF, Pennington SR, Fitzpatrick JM, et al. Biomarker research in prostate cancer-towards utility, not futility. Nat Rev Urol. 2011;8(3):131–8. [PubMed: 21394176]
62.
Epstein JI, Allsbrook WC Jr., Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228–42. [PubMed: 16096414]
63.
Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330(4):242–8. [PubMed: 8272085]
64.
Albertsen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274(8):626–31. [PubMed: 7637143]
65.
Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280(11):975–80. [PubMed: 9749479]
66.
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095–101. [PubMed: 15870412]
67.
Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of clinically localized low-grade prostate cancer: Actual 10-year and projected 15-year follow-up of the Karolinska series. Urol. 1997;50(5):722–6. [PubMed: 9372882]
68.
Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277(6):467–71. [PubMed: 9020270]
69.
Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713–9. [PubMed: 15187052]
70.
Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781–9. [PubMed: 12226148]
71.
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–84. [PubMed: 15888698]
72.
Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Canc Inst. 2010;102(13):950–8. [PMC free article: PMC2897875] [PubMed: 20562373]
73.
Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Canc Inst. 2002;94(13):981–90. [PubMed: 12096083]
74.
Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Canc Inst. 2003;95(12):868–78. [PubMed: 12813170]
75.
Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Canc Inst. 2009;101(6):374–83. [PMC free article: PMC2720697] [PubMed: 19276453]
76.
Pashayan N, Powles J, Brown C, et al. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br J Canc. 2006;95(3):401–5. [PMC free article: PMC2360645] [PubMed: 16832417]
77.
Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol. 2007;25(1):3–9. [PMC free article: PMC1913182] [PubMed: 17364211]
78.
Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008;64(1):10–9. [PubMed: 17501937]
79.
Gann PH, Han M. The natural history of clinically localized prostate cancer. JAMA. 2005;293(17):2149–51. [PubMed: 15870419]
80.
Gulati R, Wever EM, Tsodikov A, et al. What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models. Canc Epidemiol Biomarkers Prev. 2011;20(5):740–50. [PMC free article: PMC3091266] [PubMed: 21546365]
81.
Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995;172:65–72. [PubMed: 8578259]
82.
Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7(14):1–88. [PubMed: 12709289]
83.
Donovan JL, Peters TJ, Noble S, et al. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol. 2003;56(7):605–9. [PubMed: 12921927]
84.
Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81–7. [PubMed: 18783735]
85.
Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101(1):5–10. [PubMed: 17760888]
86.
Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–16. [PubMed: 2442609]
87.
Boyle P, Brawley OW. Prostate cancer: Current evidence weighs against population screening. CA Canc J Clin. 2009;59(4):220–4. [PubMed: 19564244]
88.
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Canc Inst. 2009;101(19):1325–9. [PMC free article: PMC2758309] [PubMed: 19720969]
89.
Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302(15):1685–92. [PubMed: 19843904]
90.
Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Contr Clin Trials. 2000;21(6 Suppl):273S–309S. [PubMed: 11189684]
91.
Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9. [PMC free article: PMC2944770] [PubMed: 19297565]
92.
Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38(2):83–91. [PubMed: 9973093]
93.
Labrie F, Cusan L, Gomez L, et al. Screening and treatment of localized prostate cancer decreases mortality: First analysis of the first prospectiven and randomized study on prostate cancer screening. Aging Male. 1999;2:33–43.
94.
Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59(3):311–8. [PubMed: 15042607]
95.
Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725–32. [PMC free article: PMC4089887] [PubMed: 20598634]
96.
Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8. [PubMed: 19297566]
97.
Varenhorst E, Carlsson P, Capik E, et al. Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol. 1992;31(8):815–21. [PubMed: 1290631]
98.
Sandblom G, Varenhorst E, Lofman O, et al. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol. 2004;46(6):717–23. [PubMed: 15548438]
99.
Kjellman A, Akre O, Norming U, et al. Dihydrotestosterone levels and survival in screening-detected prostate cancer: A 15-yr follow-up study. Eur Urol. 2008;53(1):106–11. [PubMed: 17482753]
100.
Kjellman A, Akre O, Norming U, et al. 15-year followup of a population based prostate cancer screening study. J Urol. 2009;181(4):1615–21. [PubMed: 19233435]
101.
Jegu J, Tretarre B, Grosclaude P, et al. Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with prostate specific antigen: French departments of Tarn and Herault. Prog Urol. 2009;19(7):487–98. [PubMed: 19559380]
102.
Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543. [PMC free article: PMC2939952] [PubMed: 20843937]
103.
Ilic D, O'Connor D, Green S, et al. Screening for prostate cancer: An updated Cochrane systematic review. BJU Int. 2011;107(6):882–91. [PubMed: 21392207]
104.
Barry MJ. Screening for prostate cancer: The controversy that refuses to die. N Engl J Med. 2009;360(13):1351–4. [PubMed: 19297564]
105.
Neal DE, Donovan JL, Martin RM, et al. Screening for prostate cancer remains controversial. Lancet. 2009;374(9700):1482–3. [PubMed: 19664817]
106.
Stark JR, Mucci L, Rothman KJ, et al. Screening for prostate cancer remains controversial. BMJ. 2009;339:b3601. [PubMed: 19778971]
107.
Roobol MJ, Carlsson S, Hugosson J. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions. Evid Base Med. 2011;16(1):20–1. [PubMed: 21228057]
108.
Pinsky PF, Blacka A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7(4):303–11. [PubMed: 20571134]
109.
Lunn RM, Bell DA, Mohler JL, et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis. 1999;20(9):1727–31. [PubMed: 10469617]
110.
Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 [PubMed: 21984740]
111.
Hanley JA. Mortality reductions produced by sustained prostate cancer screening have been underestimated. J Med Screen. 2010;17(3):147–51. [PubMed: 20956725]
112.
Vickers AJ, Roobol MJ, Lilja H. Screening for prostate cancer: Early detection or overdetection? Annu Rev Med. 2012;63:161–70. [PMC free article: PMC3415315] [PubMed: 22053739]
113.
Cavalli-Sforza LL, Bodmer WF. The Genetics of Human Populations. San Francisco: WH Freeman and Company; 1971. p. 118.
114.
Feero WG, Guttmacher AE, Collins FS. Genomic medicine: An updated primer. N Engl J Med. 2010;362(21):2001–11. [PubMed: 20505179]
115.
Qiu LX, Li RT, Zhang JB, et al. The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: A meta-analysis. Eur J Hum Genet. 2009;17(2):244–9. [PMC free article: PMC2986056] [PubMed: 18781193]
116.
Zeegers MP, Kiemeney LA, Nieder AM, et al. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Canc Epidemiol Biomarkers Prev. 2004;13(11 Pt 1):1765–71. [PubMed: 15533905]
117.
Gu M, Dong X, Zhang X, et al. The CAG repeat polymorphism of androgen receptor gene and prostate cancer: A meta-analysis. Mol Biol Rep. 2012;39(3):2615–24. [PubMed: 21667251]
118.
Chen YC, Kraft P, Bretsky P, et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Canc Epidemiol Biomarkers Prev. 2007;16(10):1973–81. [PubMed: 17932344]
119.
Li J, Coates RJ, Gwinn M, et al. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: A HuGE review. Am J Epidemiol. 2010;171(1):1–13. [PubMed: 19914946]
120.
Li X, Huang Y, Fu X, et al. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer. Mutagenesis. 2011;26(3):371–83. [PubMed: 21177315]
121.
Hong TT, Zhang RX, Wu XH, et al. Polymorphism of vascular endothelial growth factor - 1154G>A (rs1570360) with cancer risk: A meta-analysis of 16 case-control studies. Mol Biol Rep. 2011 Dec 14 [Epub ahead of print] [PubMed: 22167330]
122.
Ruiter R, Visser LE, Van Duijn CM, et al. The ACE insertion/deletion polymorphism and risk of cancer, a review and meta-analysis of the literature. Curr Canc Drug Targets. 2011;11(4):421–30. [PubMed: 21395549]
123.
Zhang Y, He J, Deng Y, et al. The insertion/deletion (I/D) polymorphism in the Angiotensin-converting enzyme gene and cancer risk: A meta-analysis. BMC Med Genet. 2011;12:159. [PMC free article: PMC3254074] [PubMed: 22151803]
124.
Geng J, Zhang Q, Zhu C, et al. XRCC1 genetic polymorphism Arg399Gln and prostate cancer risk: A meta-analysis. Urol. 2009;74(3):648–53. [PubMed: 19428062]
125.
Wei B, Zhou Y, Xu Z, et al. XRCC1 Arg399Gln and Arg194Trp polymorphisms in prostate cancer risk: A meta-analysis. Prostate Cancer Prostatic Dis. 2011;14(3):225–31. [PubMed: 21647176]
126.
Zou YF, Wang F, Feng XL, et al. Lack of association of IL-10 gene polymorphisms with prostate cancer: Evidence from 11,581 subjects. Eur J Canc. 2011;47(7):1072–9. [PubMed: 21211963]
127.
Shao N, Xu B, Mi YY, et al. IL-10 polymorphisms and prostate cancer risk: A meta-analysis. Prostate Cancer Prostatic Dis. 2011;14(2):129–35. [PubMed: 21339768]
128.
Wang N, Zhou R, Wang C, et al. -251 T/A polymorphism of the interleukin-8 gene and cancer risk: A HuGE review and meta-analysis based on 42 case-control studies. Mol Biol Rep. 2011 Jun 17 [Epub ahead of print] [PubMed: 21681427]
129.
Sun J, Hsu FC, Turner AR, et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate. 2006;66(7):728–37. [PubMed: 16425212]
130.
Murad A, Lewis SJ, Smith GD, et al. PTGS2-899G>C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. Prostate Canc Prostatic Dis. 2009;12(3):296–300. [PubMed: 19488068]
131.
Danforth KN, Rodriguez C, Hayes RB, et al. TNF polymorphisms and prostate cancer risk. Prostate. 2008;68(4):400–7. [PubMed: 18196539]
132.
Xu B, Tong N, Chen SQ, et al. FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls. BMC Canc. 2011;11:84. [PMC free article: PMC3049742] [PubMed: 21349172]
133.
Liwei L, Chunyu L, Jie L, et al. Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: A meta-analysis. Urol Int. 2011;87(2):159–64. [PubMed: 21625079]
134.
Wei BB, Xi B, Wang R, et al. TGFbeta1 T29C polymorphism and cancer risk: A meta-analysis based on 40 case-control studies. Canc Genet Cytogenet. 2010;196(1):68–75. [PubMed: 19963138]
135.
Liao RY, Mao C, Qiu LX, et al. TGFBR1*6A/9A polymorphism and cancer risk: A meta-analysis of 13,662 cases and 14,147 controls. Mol Biol Rep. 2010;37(7):3227–32. [PubMed: 19882361]
136.
Chen X, Guan J, Song Y, et al. IGF-I (CA) repeat polymorphisms and risk of cancer: A meta-analysis. J Hum Genet. 2008;53(3):227–38. [PubMed: 18188667]
137.
Li L, Huang X, Huo K. IGFBP3 polymorphisms and risk of cancer: A meta-analysis. Mol Biol Rep. 2010;37(1):127–40. [PubMed: 19449212]
138.
Bai JL, Zheng MH, Xia X, et al. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls. Eur J Canc. 2009;45(8):1443–9. [PubMed: 19223177]
139.
Collin SM, Metcalfe C, Zuccolo L, et al. Association of folate-pathway gene polymorphisms with the risk of prostate cancer: A population-based nested case-control study, systematic review, and meta-analysis. Canc Epidemiol Biomarkers Prev. 2009;18(9):2528–39. [PubMed: 19706844]
140.
Mao C, Qiu LX, Zhan P, et al. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: A meta-analysis involving 8,962 subjects. J Canc Res Clin Oncol. 2010;136(7):975–9. [PubMed: 20012093]
141.
Zhang H, Xu Y, Zhang Z, et al. The hOGG1 Ser326Cys polymorphism and prostate cancer risk: A meta-analysis of 2584 cases and 3234 controls. BMC Canc. 2011;11:391. [PMC free article: PMC3224345] [PubMed: 21914193]
142.
Shaik AP, Jamil K, Das P. CYP1A1 polymorphisms and risk of prostate cancer. A meta-analysis. Urol J. 2009;6(2):78–86. [PubMed: 19472123]
143.
Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: A HuGE review. Am J Epidemiol. 2004;160(9):825–41. [PubMed: 15496535]
144.
Wang F, Zou YF, Feng XL, et al. CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies. Prostate. 2011;71(11):1167–77. [PubMed: 21656827]
145.
Cai L, Huang W, Chou KC. Prostate cancer with variants in CYP17 and UGT2B17 genes: A meta-analysis. Protein Pept Lett. 2011 [PubMed: 21919858]
146.
Mo Z, Gao Y, Cao Y, et al. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: A HuGE review. Prostate. 2009;69(6):662–88. [PubMed: 19143011]
147.
Raimondi S, Johansson H, Maisonneuve P, et al. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170–80. [PubMed: 19403841]
148.
Xu B, Tong N, Li JM, et al. ELAC2 polymorphisms and prostate cancer risk: A meta-analysis based on 18 case-control studies. Prostate Cancer Prostatic Dis. 2010;13(3):270–7. [PMC free article: PMC2922791] [PubMed: 20231859]
149.
Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: A meta-analysis. Clin Canc Res. 2006;12(19):5713–9. [PubMed: 17020975]
150.
Wei B, Xu Z, Ruan J, et al. RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: Evidences from a meta-analysis. Mol Biol Rep. 2012;39(3):2347–53. [PubMed: 21656378]
151.
Zhu Y, Wang J, He Q, et al. Association of p53 codon 72 polymorphism with prostate cancer: A meta-analysis. Mol Biol Rep. 2011;38(3):1603–7. [PubMed: 20842446]
152.
Li MS, Liu JL, Wu Y, et al. Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk. Genet Mol Res. 2011;10(4):2924–33. [PubMed: 22179964]
153.
Wo X, Han D, Sun H, et al. MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis. J Genet Genomics. 2011;38(8):341–50. [PubMed: 21867960]
154.
Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29(3):306–9. [PubMed: 11600885]
155.
Hirschhorn JN, Lohmueller K, Byrne E, et al. A comprehensive review of genetic association studies. Genet Med. 2002;4(2):45–61. [PubMed: 11882781]
156.
Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33(2):177–82. [PubMed: 12524541]
157.
McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nat Rev Genet. 2008;9(5):356–69. [PubMed: 18398418]
158.
Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39(5):645–9. [PubMed: 17401363]
159.
Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5):631–7. [PubMed: 17401366]
160.
Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007;39(8):977–83. [PubMed: 17603485]
161.
Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310–5. [PubMed: 18264096]
162.
Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281–3. [PMC free article: PMC3598012] [PubMed: 18264098]
163.
Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316–21. [PubMed: 18264097]
164.
Sun J, Zheng SL, Wiklund F, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 2009;69(1):10–5. [PMC free article: PMC2705898] [PubMed: 19117981]
165.
Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009;41(10):1122–6. [PMC free article: PMC3562712] [PubMed: 19767754]
166.
Takata R, Akamatsu S, Kubo M, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42(9):751–4. [PubMed: 20676098]
167.
Haiman CA, Chen GK, Blot WJ, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011;43(6):570–3. [PMC free article: PMC3102788] [PubMed: 21602798]
168.
Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10):1116–21. [PMC free article: PMC2846760] [PubMed: 19767753]
169.
Schumacher FR, Berndt SI, Siddiq A, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011;20(19):3867–75. [PMC free article: PMC3168287] [PubMed: 21743057]
170.
Kote-Jarai Z, Olama AA, Giles GG, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet. 2011;43(8):785–91. [PMC free article: PMC3396006] [PubMed: 21743467]
171.
Nam RK, Zhang W, Siminovitch K, et al. New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther. 2011;12(11):997–1004. [PMC free article: PMC3280918] [PubMed: 22130093]
172.
Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet. 2001;357(9257):709–12. [PubMed: 11247571]
173.
Khoury MJ, Yang Q, Gwinn M, et al. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med. 2004;6(1):38–47. [PubMed: 14726808]
174.
Madlensky L, McLaughlin JR, Carroll JC, et al. Risks and benefits of population-based genetic testing for Mendelian subsets of common diseases were examined using the example of colorectal cancer risk. J Clin Epidemiol. 2005;58(9):934–41. [PubMed: 16085197]
175.
Janssens AC, Gwinn M, Bradley LA, et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet. 2008;82(3):593–9. [PMC free article: PMC2427295] [PubMed: 18319070]
176.
Yang Q, Khoury MJ, Friedman JM, et al. On the use of population attributable fraction to determine sample size for case-control studies of gene-environment interaction. Epidemiol. 2003;14(2):161–7. [PubMed: 12606881]
177.
Yang Q, Khoury MJ, Friedman J, et al. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol. 2005;34(5):1129–37. [PubMed: 16043441]
178.
Yang Q, Khoury MJ, Botto L, et al. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Gen. 2003;72(3):636–49. [PMC free article: PMC1180239] [PubMed: 12592605]
179.
Hawken SJ, Greenwood CM, Hudson TJ, et al. The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancer. Hum Genet. 2010;128(1):89–101. [PMC free article: PMC2885303] [PubMed: 20437058]
180.
Janssens AC, Ioannidis JP, Van Duijn CM, et al. Strengthening the reporting of genetic risk prediction studies: The GRIPS Statement. Ann Intern Med. 2011;154(6):421–5. [PubMed: 21403077]
181.
Lu X, Zhang K, Van SC, et al. An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models. BMC Med Genomics. 2010;3:23. [PMC free article: PMC2901344] [PubMed: 20569491]
182.
Yoon PW, Scheuner MT, Khoury MJ. Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med. 2003;24(2):128–35. [PubMed: 12568818]
183.
Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med. 2009;11(1):3–14. [PMC free article: PMC2743609] [PubMed: 18813139]
184.
Hindorff LA, MacArthur J, Wise A, et al. A catalog of published genome-wide association studies. 2011.
185.
Wells GA, Shea B, O'Connel D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quailty of nonrandomised studies in meta-analyses. Feb 1, 2009. [June 12, 2012]. 2009 Feb 1. www​.ohri.ca/programs​/clinical_epidemiology/oxford.htm.
186.
Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25. [PMC free article: PMC305345] [PubMed: 14606960]
187.
GRADE Working Group. Grading the quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. [June 12, 2012]; www​.gradeworkinggroup.org. [PMC free article: PMC428525] [PubMed: 15205295]
188.
Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910–9. [PubMed: 18199855]
189.
Salinas CA, Koopmeiners JS, Kwon EM, et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate. 2009;69(4):363–72. [PMC free article: PMC2788301] [PubMed: 19058137]
190.
Sun J, Chang BL, Isaacs SD, et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate. 2008;68(12):1257–62. [PMC free article: PMC2800258] [PubMed: 18491292]
191.
Helfand BT, Fought AJ, Loeb S, et al. Genetic prostate cancer risk assessment: Common variants in 9 genomic regions are associated with cumulative risk. J Urol. 2010;184(2):501–5. [PMC free article: PMC3164535] [PubMed: 20620408]
192.
Zheng SL, Sun J, Wiklund F, et al. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Canc Res. 2009;15(3):1105–11. [PMC free article: PMC3187807] [PubMed: 19188186]
193.
Xu J, Sun J, Kader AK, et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate. 2009;69(14):1565–72. [PMC free article: PMC2793526] [PubMed: 19562736]
194.
Sun J, Lange EM, Isaacs SD, et al. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate. 2008;68(5):489–97. [PubMed: 18213635]
195.
Nam RK, Zhang WW, Trachtenberg J, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Canc Res. 2009;15(5):1787–93. [PubMed: 19223501]
196.
Beuten J, Gelfond JA, Franke JL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Canc Epidemiol Biomarkers Prev. 2009;18(6):1869–80. [PubMed: 19505920]
197.
Penney KL, Salinas CA, Pomerantz M, et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Canc Res. 2009;15(9):3223–30. [PMC free article: PMC2878092] [PubMed: 19366828]
198.
Sun J, Kader AK, Hsu FC, et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate. 2011;71(4):421–30. [PMC free article: PMC3025084] [PubMed: 20878950]
199.
Helfand BT, Kan D, Modi P, et al. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a “normal” prostate specific antigen and digital rectal examination. Prostate. 2011;71(4):394–402. [PMC free article: PMC3089434] [PubMed: 20860009]
200.
Aly M, Wiklund F, Xu J, et al. Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 cohort study. Eur Urol. 2011;60(1):21–8. [PMC free article: PMC4417350] [PubMed: 21295399]
201.
Wiklund FE, Adami HO, Zheng SL, et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Canc Epidemiol Biomarkers Prev. 2009;18(5):1659–62. [PMC free article: PMC3353269] [PubMed: 19423541]
202.
Zheng SL, Stevens VL, Wiklund F, et al. Two independent prostate cancer risk-associated Loci at 11q13. Canc Epidemiol Biomarkers Prev. 2009;18(6):1815–20. [PMC free article: PMC2802212] [PubMed: 19505914]
203.
Ekhart C, Rodenhuis S, Smits PH, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenetics & Genomics. 2008;18(11):1009–15. [PubMed: 18854779]
204.
Helfand BT, Loeb S, Meeks JJ, et al. Pathological outcomes associated with the 17q prostate cancer risk variants. J Urol. 2009;181(6):2502–7. [PMC free article: PMC3140699] [PubMed: 19371897]
205.
Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38(6):652–8. [PubMed: 16682969]
206.
Xu J, Zheng L, Gronberg H, Isaac W. Methods and compositions for correlating genetic markers with prostate cancer risk. United States Patent Application Publication: 2009. Jul 18, 2011.
207.
Zheng L, Xu J, Trent J, Bleecker E, Turner A. Proactive Genomics. 2008.
208.
deCODEhealth. 2011. [June 12, 2012]. www​.decodehealth.com/prostate-cancer.
209.
deCODEme. 2011. [June 12, 2012]. www​.decodeme.com/complete-genetic-scan.
210.
Gudmundsson J, Sulem P. Genetic variants contributing to risk of prostate cancer. United States Patent Application Publication: 2011. Jul 18, 2011. [June 12, 2012]. www​.freepatentsonline​.com/20110020320.pdf.
211.
Beuten J, Gelfond JA, Byrne JJ, et al. CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis. 2008;29(9):1751–7. [PMC free article: PMC2527647] [PubMed: 18544568]
212.
Hernandez J, Balic I, Johnson-Pais TL, et al. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol. 2006;175(2):523–7. [PubMed: 16406987]
213.
Torkko KC, van BA, Mai P, et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Canc Res. 2008;14(10):3223–9. [PubMed: 18483391]
214.
Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Canc Inst. 2007;99(24):1836–44. [PubMed: 18073375]
215.
Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J Natl Canc Inst. 2000;92(14):1151–8. [PubMed: 10904088]
216.
Ardlie KG, Lunetta KL, Seielstad M. Testing for population subdivision and association in four case-control studies. Am J Hum Genet. 2002;71(2):304–11. [PMC free article: PMC379163] [PubMed: 12096349]
217.
Millikan RC. Re: Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J Natl Canc Inst. 2001;93(2):156–8. [PubMed: 11208892]
218.
Ioannidis JP, Ntzani EE, Trikalinos TA. ‘Racial’ differences in genetic effects for complex diseases. Nat Genet. 2004;36(12):1312–8. [PubMed: 15543147]
219.
Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005;97(14):1043–55. [PubMed: 16030302]
220.
Pan Z, Trikalinos TA, Kavvoura FK, et al. Local literature bias in genetic epidemiology: An empirical evaluation of the Chinese literature. PLoS Med. 2005;2(12):e334. [PMC free article: PMC1285066] [PubMed: 16285839]
221.
Tucker JD, Chang H, Brandt A, et al. An empirical analysis of overlap publication in Chinese language and English research manuscripts. PLoS One. 2011;6(7):e22149. [PMC free article: PMC3134484] [PubMed: 21765946]
222.
Moher D, Pham B, Lawson ML, et al. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7(41):1–90. [PubMed: 14670218]
223.
Xu J, Zheng SL, Carpten JD, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Gen. 2001;68(4):901–11. [PMC free article: PMC1275644] [PubMed: 11254448]
224.
Nam RK, Zhang WW, Loblaw DA, et al. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Canc Prostatic Dis. 2008;11(3):241–6. [PubMed: 17876339]
225.
Nam RK, Zhang WW, Jewett MA, et al. The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Canc Res. 2005;11(23):8391–7. [PubMed: 16322300]
226.
Nam RK, Zhang WW, Klotz LH, et al. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Canc Res. 2006;12(21):6452–8. [PubMed: 17085659]
227.
Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Canc. 2006;5(1):61–6. [PubMed: 16859581]
228.
Eng J. Receiver operating characteristic analysis: a primer. Acad Radiol. 2005;12(7):909–16. [PubMed: 16039544]
229.
Fan J, Upandhye S, Worster A. Understanding receiver operating characteristic (ROC) curves: Pedagogical tools and methods. CJEM. 2006;8(1):19–20. [PubMed: 17175625]
230.
Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiol. 2010;21(1):128–38. [PMC free article: PMC3575184] [PubMed: 20010215]
231.
Vickers AJ, Cronin AM. Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: Towards a decision analytic framework. Semin Oncol. 2010;37(1):31–8. [PMC free article: PMC2857322] [PubMed: 20172362]
232.
Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: How can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007;9(10):665–74. [PubMed: 18073579]
233.
Burke W, Burton H, Hall AE, et al. Extending the reach of public health genomics: What should be the agenda for public health in an era of genome-based and “personalized” medicine? Genet Med. 2010;12(12):785–91. [PubMed: 21189494]
234.
Miesfeldt S, Jones SM, Cohn W, et al. Men's attitudes regarding genetic testing for hereditary prostate cancer risk. Urol. 2000;55(1):46–50. [PubMed: 10654893]
235.
Myers RE, Hyslop T, Jennings-Dozier K, et al. Intention to be tested for prostate cancer risk among African-American men. Canc Epidemiol Biomarkers Prev. 2000;9(12):1323–8. [PubMed: 11142417]
236.
Doukas DJ, Li Y. Men's values-based factors on prostate cancer risk genetic testing: A telephone survey. BMC Med Genet. 2004;5:28. [PMC free article: PMC544862] [PubMed: 15588314]
237.
Schwartz LM, Woloshin S, Fowler FJ Jr., et al. Enthusiasm for cancer screening in the United States. JAMA. 2004;291(1):71–8. [PubMed: 14709578]
238.
Cowan R, Meiser B, Giles GG, et al. The beliefs, and reported and intended behaviors of unaffected men in response to their family history of prostate cancer. Genet Med. 2008;10(6):430–8. [PubMed: 18496220]
239.
Goodwin JS, Singh A, Reddy N, et al. Overuse of screening colonoscopy in the medicare population. Arch Intern Med. 2011 [PMC free article: PMC3856662] [PubMed: 21555653] [CrossRef]
240.
Wilson BJ, Qureshi N, Santaguida P, et al. Systematic review: Family history in risk assessment for common diseases. Ann Intern Med. 2009;151(12):878–85. [PubMed: 19884616]
241.
Palomaki GE, Melillo S, Neveux L, et al. Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies--A targeted evidence-based review. Genet Med. 2010;12(12):772–84. [PubMed: 21045709]
242.
Vickers AJ, Lilja H. Predicting prostate cancer many years before diagnosis: How and why? World J Urol. 2011 [PMC free article: PMC3373007] [PubMed: 22101902]
243.
Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435–48. [PubMed: 18252677]
244.
MacInnis RJ, Antoniou AC, Eeles RA, et al. A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact. Genetic Epidemiology. 2011;35(6):549–56. [PMC free article: PMC3950816] [PubMed: 21769933]
245.
Machiela MJ, Chen CY, Chen C, et al. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genetic Epidemiology. 2011;35(6):506–14. [PMC free article: PMC4089860] [PubMed: 21618606]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.4M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...